Login
$TRAW
$0.26 +$0.00 (0.0%) After hours

$TRAW 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Date of Report (Date of earliest event reported): November 16, 2026

12 Nov 2026 8-K: Regulation FD Disclosure

Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®

23 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of October 23, 2026 (this “Agreement”), by and between Roth Principal Investments, LLC, a Delaware limited liability company (the “Investor”), and Traws Pharma, Inc., a Del...

14 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study

31 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for...

10 Jul 2026 8-K: Other Events

We have acted as counsel to Traws Pharma, Inc., a Delaware corporation (the “Company”), in connection with the offering and sale (the “Offering”) of shares of common stock of the Company, par value $0.01 per share, with an aggregate publ...

09 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Effective as of November 21, 2025, Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) (the “Company”) established the Traws Pharma, Inc. 2021 Incentive Compensation Plan (the “Plan”). By adoption of this instrument, the Company now d...

22 Jun 2026 8-K: Regulation FD Disclosure

Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed

12 Jun 2026 8-K: Regulation FD Disclosure

NEWTOWN, PA — June 12, 2026 — (GLOBENEWSWIRE) Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test ...

27 May 2026 8-K: Regulation FD Disclosure

Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa

26 May 2026 8-K: Other Events

We have acted as counsel to Traws Pharma, Inc., a Delaware corporation (the “Company”), in connection with the offering and sale (the “Offering”) of shares of common stock of the Company, par value $0.01 per share, with an aggregate publ...

15 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027

15 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,

15 Apr 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 15 2026, by and among Traws Pharma, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, a...

19 Feb 2026 8-K: Other Events

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

26 Jan 2026 8-K: Other Events

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

13 Jan 2026 8-K: Other Events

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

17 Dec 2025 8-K: Other Events

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

16 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

(As amended and restated, effective on the Restatement Effective Date)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support